Latest clinical trials
- 2 days ago: Rheumatoid Arthritis
- 4 days ago: Gestational Hypertension
- 8 days ago: Epilepsy
- 9 days ago: Non Small Cell Lung Cancer
- 9 days ago: Pancreatic Cancer
- 9 days ago: Colorectal Cancer
- 14 days ago: Cardiac Arrest
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: placebo; Drug: Disease-modifying antirheumatic drugs (DMARDs)
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified September 2010
Full details...
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: placebo; Drug: Disease-modifying antirheumatic drugs (DMARDs)
Sponsor: Hoffmann-La Roche
Not yet recruiting - verified September 2010
Full details...
Condition: Gestational Hypertension
Interventions: Procedure: Intervention is blood pressure management approach; Procedure: Intervention is blood pressure management approach.
Sponsors: University of British Columbia; Canadian Institutes of Health Research (CIHR); The Centre for Mother, Infant and Child Research (CMICR), University of Toronto
Recruiting - verified August 2010
Full details...
Interventions: Procedure: Intervention is blood pressure management approach; Procedure: Intervention is blood pressure management approach.
Sponsors: University of British Columbia; Canadian Institutes of Health Research (CIHR); The Centre for Mother, Infant and Child Research (CMICR), University of Toronto
Recruiting - verified August 2010
Full details...
Condition: Epilepsy
Intervention: Drug: USL255
Sponsor: Upsher-Smith Laboratories
Not yet recruiting - verified August 2010
Full details...
Intervention: Drug: USL255
Sponsor: Upsher-Smith Laboratories
Not yet recruiting - verified August 2010
Full details...
Condition: Non Small Cell Lung Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Full details...
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Full details...
Condition: Pancreatic Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Full details...
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Full details...
Condition: Colorectal Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Full details...
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Full details...
Condition: Cardiac Arrest
Interventions: Device: Automated CPR; Device: ECMO; Procedure: Coronary angiography; Procedure: Therapeutic Hypothermia
Sponsors: Bayside Health; The Alfred; Ambulance Victoria; Zoll Medical Corporation
Not yet recruiting - verified August 2010
Full details...
Interventions: Device: Automated CPR; Device: ECMO; Procedure: Coronary angiography; Procedure: Therapeutic Hypothermia
Sponsors: Bayside Health; The Alfred; Ambulance Victoria; Zoll Medical Corporation
Not yet recruiting - verified August 2010
Full details...
Dr Thomas Beddoes was an English scientist, physician, and activist for democracy during the French Revolution (1760 - 1808). He studied chemistry
at Oxford and medicine at Edinburgh. He made European scientific literature accessible to his colleagues and published practical advice for the public.
Dr Beddoes understood that:
- Lifestyle, diet and physical activity profoundly influenced health
- Pharmaceutical innovation was essential for the treatment of disease
- Good evidence was the only basis of sound clinical judgement
- Hospital care had to be linked closely to cost-effective community care
- Effective treatments required patients' compliance and at times social change
- Community wellness would follow practical and accessible public education
